Get started
JOHNSON + JOHNSON DL 1JOHNSON + JOHNSON DL 1JOHNSON + JOHNSON DL 1

JOHNSON + JOHNSON DL 1

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Bonds

JNJ trade ideas

The Baby Powder Gives You Cancer! 😯 (JNJ)📈 Failed to breach through the highs, but the fight ain't over yet! Downward channel identified. Seeing a lot of rejection at this channel top as we approach a critical level of support at 143.47. You want to long when the downward black Resistance gets cracked. Otherwise short 143.47 break and see if the bottom channel support holds. Critical to use the ema dots and the Crossover strategy at that 143.47 level for a more aggressive long if held. Could be double top or could be cup and handle. 🤷‍♂️ Play the channel. Best of luck! 🎲 🥇MLT | MAJOR LEAGUE TRADER
NYSE:JNJ
by UnknownUnicorn2319099
JNJ - Where's that vaccine?I bought JNJ at $125 mainly because it seemed like it would have a strong bounce back considering the reason why the market crashed in the first place. Looking at the broader market, this may be a consolidation period. Although, we have a lot of sell signals right now. 1. 10/21 EMA sell signal 2. Weak Buying Power 3. Double Top? Would only confirm if it breaks the lows in march. So we are really far from that but that would be very bearish if so. 4. Rising Wedge post downtrend. Not the most reliable signal. The better question is the bull flag scenario. Is this a bull flag? With the rest of the market pushing higher, I almost believe that it is. Either way, I bought it for the LONG considering how solid of a company it is (and will only become stronger after this).
NYSE:JNJ
by ChrisPtaco_32
Johnson & Johnson Technical AnalysisWait Before buying - check if the support level will not be broken before buying, otherwise hold Fundamental Analysis Johnson & Johnson (NYSE:JNJ) began researching vaccine candidates in January, as soon as the COVID-19 sequence became available. A Phase 1 clinical trial of the novel coronavirus vaccine is planned for September, with data regarding safety and efficacy available by the end of the year. If all goes accordingly, the vaccine could be ready “for emergency use” in early 2021. As part of this commitment, Johnson & Johnson will scale up its manufacturing capacity in the U.S. and other countries in order to enable the supply of more than 1 billion doses of the vaccine when it is ready.
NYSE:JNJ
by Mauriello